Compare APLT & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APLT | ICU |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0M | 15.9M |
| IPO Year | 2019 | N/A |
| Metric | APLT | ICU |
|---|---|---|
| Price | $0.10 | $2.55 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.25 | N/A |
| AVG Volume (30 Days) | ★ 11.6M | 155.6K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,000,000.00 | $881,000.00 |
| Revenue This Year | $124.18 | $691.85 |
| Revenue Next Year | $25.00 | $64.17 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1195.59 |
| 52 Week Low | $0.09 | $2.20 |
| 52 Week High | $1.50 | $30.70 |
| Indicator | APLT | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 28.21 | 73.69 |
| Support Level | $0.09 | $2.49 |
| Resistance Level | $0.10 | $2.98 |
| Average True Range (ATR) | 0.01 | 0.19 |
| MACD | 0.02 | 0.13 |
| Stochastic Oscillator | 34.74 | 83.69 |
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.